RecruitingCachexia

A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia

Eligible age

18+ yrs

Accepts

All genders

Locations

10 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This open label ascending dose study is designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AV-380 in cancer patients with Cachexia. AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.

Sponsor: AVEO Pharmaceuticals, Inc.

You may qualify if…

✓ 1. Patient must be ≥ 18 years of age at the time of signing the informed consent.
✓ 2. Patients with histologically confirmed solid tumor cancer who are actively receiving SoC therapy for this cancer.
✓ 3. Patients with cachexia as defined by Fearon criteria:
✓ 1. Weight loss \> 5% over past 6 months (in absence of simple starvation), or
✓ 2. BMI \< 20 kg/m2 and any degree of weight loss \> 2%, or
✓ 3. Sarcopenia and any degree of weight loss \> 2%
✓ 4. Patients with life expectancy ≥ 3 months

You may not qualify if…

✕ 1. History of allergic or anaphylactic reaction to any monoclonal antibody (IgG protein) or molecules made of components of monoclonal antibody
✕ 2. Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 2 weeks before first dose of study treatment.
✕ 3. Myocardial infarction or heart failure of New York Heart Association Grade 3-4 within 3 months prior to start of protocol therapy
✕ 4. Uncontrolled pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)
✕ 5. Cachexia is caused by other reasons (e.g., severe chronic obstructive pulmonary disease, heart failure, or HIV/AIDS), or the patient has uncontrolled reversible causes of reduced oral food intake, including, but not limited to, oral mucositis, nausea/vomiting, diarrhea, and/or obstruction, impairing the patient's ability to eat as determined by the Investigator.
✕ 6. Patients receiving tube feedings or parenteral nutrition at the time of Screening.